Gonadotropin-releasing Hormone Analog

Phase 2Biologic

Gonadotropin-releasing Hormone Analog is one of 56 biologic programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Prostate CancerActive, not recruiting

Stage II Prostate AdenocarcinomaActive, not recruiting

Breast CancerPhase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Stage II Prostate AdenocarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

Avastin

BBio-Thera Solutions

Preclinical

153 3

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 4

Megace

Bristol-Myers Squibb

Preclinical

4 5

Voltaren

Novartis

Preclinical

1 6

Gonadotropin-releasing Hormone Analog

UUniversity of Washington

Phase 2

1 7

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 8

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 9

Zinecard

CChildren's Oncology Group

Preclinical

2 10

Spravato

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Prostate Cancer

NCT06369610

Phase 2Active, not recruiting

Stage II Prostate Adenocarcinoma

NCT02949284

Q2 2028

Phase 2Recruiting

Breast Cancer

NCT06179303

Q2 2029

Phase 2Not yet recruiting

Prostate Cancer

NCT07466498

Clinical

Trials by Indication[1]

Prostate Cancer3 trials

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

Recruiting·MMayo Clinic·Phase 2·NCT06369610·110 enrolled

Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03279250·86 enrolled

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

Not yet recruiting·UUniversity of Washington·Phase 2·NCT07466498·60 enrolled

Breast Cancer1 trial

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Recruiting·UUniversity of Washington·Phase 2·NCT06179303·60 enrolled

Stage II Prostate Adenocarcinoma1 trial

Randomized Three-Arm Trial to Evaluate the Effect of Neoadjuvant Apalutamide Alone or in Combination With Abiraterone Acetate and GnRH Agonist on Enhancing Surgical Outcome of Nerve-Sparing Radical Prostatectomy in Men With High-Risk Prostate Cancer

Active, not recruiting·RRutgers, The State University of New Jersey·Phase 2·NCT02949284·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Gonadotropin-releasing Hormone Analog. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gonadotropin-releasing Hormone Analog compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gonadotropin-releasing Hormone Analog. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Washington company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Washington

Gonadotropin-releasing Hormone Analog

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Q2 2029

Trials by Indication[1]

Prostate Cancer3 trials

Breast Cancer1 trial

Stage II Prostate Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News